title: Anaplastic Thyroid Carcinoma, Version 2.2015.
abstract: This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer.
authors.forename: Robert I
authors.initials: RI
authors.lastname: Haddad
authors.forename: William M
authors.initials: WM
authors.lastname: Lydiatt
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Ball
authors.forename: Naifa Lamki
authors.initials: NL
authors.lastname: Busaidy
authors.forename: David
authors.initials: D
authors.lastname: Byrd
authors.forename: Glenda
authors.initials: G
authors.lastname: Callender
authors.forename: Paxton
authors.initials: P
authors.lastname: Dickson
authors.forename: Quan-Yang
authors.initials: QY
authors.lastname: Duh
authors.forename: Hormoz
authors.initials: H
authors.lastname: Ehya
authors.forename: Megan
authors.initials: M
authors.lastname: Haymart
authors.forename: Carl
authors.initials: C
authors.lastname: Hoh
authors.forename: Jason P
authors.initials: JP
authors.lastname: Hunt
authors.forename: Andrei
authors.initials: A
authors.lastname: Iagaru
authors.forename: Fouad
authors.initials: F
authors.lastname: Kandeel
authors.forename: Peter
authors.initials: P
authors.lastname: Kopp
authors.forename: Dominick M
authors.initials: DM
authors.lastname: Lamonica
authors.forename: Judith C
authors.initials: JC
authors.lastname: McCaffrey
authors.forename: Jeffrey F
authors.initials: JF
authors.lastname: Moley
authors.forename: Lee
authors.initials: L
authors.lastname: Parks
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Raeburn
authors.forename: John A
authors.initials: JA
authors.lastname: Ridge
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Ringel
authors.forename: Randall P
authors.initials: RP
authors.lastname: Scheri
authors.forename: Jatin P
authors.initials: JP
authors.lastname: Shah
authors.forename: Robert C
authors.initials: RC
authors.lastname: Smallridge
authors.forename: Cord
authors.initials: C
authors.lastname: Sturgeon
authors.forename: Thomas N
authors.initials: TN
authors.lastname: Wang
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Wirth
authors.forename: Karin G
authors.initials: KG
authors.lastname: Hoffmann
authors.forename: Miranda
authors.initials: M
authors.lastname: Hughes
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D050397:Radiotherapy, Intensity-Modulated; D043823:Taxoids / Q000008:administration & dosage; D065646:Thyroid Carcinoma, Anaplastic / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D013965:Thyroidectomy
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D016190:Carboplatin; D017239:Paclitaxel